Abemaciclib for Treatment of Advanced Bone and Soft Tissue Sarcoma Identified as Having CDK Pathway Alteration

This study is testing a targeted cancer medicine called Abemaciclib to see how well it works against advanced bone and soft tissue sarcomas. Researchers want to help patients whose tumors have a specific genetic feature by blocking cancer cell growth.

You might be able to join if you have advanced bone or soft tissue sarcoma, have certain previous treatments depending on your cancer type, and your tumor tissue shows specific testing results. Your doctor can help review your past treatments to see if you qualify.

Participants will take the Abemaciclib medication as pills by mouth twice a day. You will keep taking this medicine for as long as it is helping and you are not experiencing severe side effects.

This study is currently recruiting patients at locations in Jacksonville, Florida, Iowa City, Iowa, and St. Louis, Missouri. The study team will monitor your progress closely throughout your participation.